Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Clin Cancer Res. 2016 Sep 15;23(1):73–80. doi: 10.1158/1078-0432.CCR-15-3169

Fig. 3. Sphere formation is reduced with hERG blockers.

Fig. 3

HERG specific blockerbE-4031 was used in increasing concentrations on 12.1, 22, 112, and 114 GPDCs. After two weeks of drug treatment, the number of spheres were counted and normalized to vehicle control. (*= p-value <0.05)